Wellbutrin Indirect Buyers Seek Cert. In Antitrust Suit

Law360, New York (December 15, 2009, 2:05 PM EST) -- A group of employee benefit plans has moved to certify a class of plaintiffs that paid or reimbursed for Wellbutrin XL, in an action accusing Biovail Corp. and GlaxoSmithKline PLC of suppressing the market for a generic version of the blockbuster antidepressant.

In the U.S. District Court for the Eastern District of Pennsylvania on Monday, the employee plans moved to certify a class of entities or individuals who have paid or reimbursed for some or all of the costs of the drug or an AB-rated generic...
To view the full article, register now.